Eupraxia Pharmaceuticals Reports EREFS Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week (DDW)

Clinical Trial Progression and Validation

• Latest Release (May 5, 2026): Eupraxia presented EREFS (Eosinophilic Esophagitis Endoscopic Reference Score) data from the Phase 1b/2a RESOLVE trial at Digestive Disease Week.
• Key Finding: A direct relationship exists between injection count and clinical improvement; 20 injections resulted in a mean EREFS reduction of 65% at week 12 for patients with baseline scores >2.
• Dose Optimization: Higher dose cohorts (8b and 9, consisting of 20x6mg and 20x8mg doses) showed near-complete EREFS improvement.
• Phase 2b Status: The randomized placebo-controlled Phase 2b portion is recruiting the 120mg (20x6mg) and 160mg (20x8mg) doses, with top-line data expected in Q4 2026.

Evaluation of News Significance

• Expectation vs. Reality: The market has been tracking the RESOLVE trial closely since late 2025. The confirmation of a dose-response relationship and the resolution of catheter issues (March) were anticipated steps toward Phase 2b design. This news confirms those expectations rather than introducing a surprise breakthrough.
• Market Impact: While positive, the data is incremental to the strong clinical narrative established in January and April. It solidifies the dosing regimen for the pivotal Phase 2b study but does not alter the fundamental risk profile of the asset significantly beyond what was already priced into the stock following the Jan/April announcements.
• Catalyst Timing: The next major catalyst is Q4 2026 top-line data from the Phase 2b trial. This news serves as a bridge, reducing uncertainty about the dosing strategy but not removing the binary risk of Phase 2b failure.

Corporate Profile

• Company: Eupraxia Pharmaceuticals Inc.
• Flagship Asset: EP-104GI (Diffusphere™ technology).
• Indication: Eosinophilic Esophagitis (EoE), with plans to expand to esophageal strictures and fibrostenotic Crohn’s disease.
• Mechanism: Long-acting submucosal corticosteroid formulation designed for local delivery via injection into esophageal tissues to address inflammation and fibrosis.